BRPI0213653B8 - formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo - Google Patents

formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo

Info

Publication number
BRPI0213653B8
BRPI0213653B8 BRPI0213653A BR0213653A BRPI0213653B8 BR PI0213653 B8 BRPI0213653 B8 BR PI0213653B8 BR PI0213653 A BRPI0213653 A BR PI0213653A BR 0213653 A BR0213653 A BR 0213653A BR PI0213653 B8 BRPI0213653 B8 BR PI0213653B8
Authority
BR
Brazil
Prior art keywords
phenol
propyl
dimethyl
ethyl
amino
Prior art date
Application number
BRPI0213653A
Other languages
English (en)
Portuguese (pt)
Other versions
BRPI0213653B1 (pt
BR0213653A (pt
Inventor
Ziegler Iris
Bartholomaus Johannes
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0213653(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR0213653A publication Critical patent/BR0213653A/pt
Publication of BRPI0213653B1 publication Critical patent/BRPI0213653B1/pt
Publication of BRPI0213653B8 publication Critical patent/BRPI0213653B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0213653A 2001-10-24 2002-10-22 formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo BRPI0213653B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE101524692 2001-10-24
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2002/011809 WO2003035053A1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Publications (3)

Publication Number Publication Date
BR0213653A BR0213653A (pt) 2004-10-26
BRPI0213653B1 BRPI0213653B1 (pt) 2018-04-03
BRPI0213653B8 true BRPI0213653B8 (pt) 2021-05-25

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0213653A BRPI0213653B8 (pt) 2001-10-24 2002-10-22 formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo

Country Status (28)

Country Link
US (7) US20050058706A1 (enExample)
EP (1) EP1439829B1 (enExample)
JP (2) JP4758064B2 (enExample)
KR (1) KR100958045B1 (enExample)
CN (1) CN100402021C (enExample)
AR (1) AR036943A1 (enExample)
AT (1) ATE303802T1 (enExample)
AU (1) AU2002349001C1 (enExample)
BR (1) BRPI0213653B8 (enExample)
CA (1) CA2464578C (enExample)
CO (1) CO5570662A2 (enExample)
CY (1) CY2012022I1 (enExample)
DE (1) DE50204198D1 (enExample)
DK (1) DK1439829T3 (enExample)
EC (1) ECSP045102A (enExample)
ES (1) ES2248622T3 (enExample)
HU (1) HU230161B1 (enExample)
IL (2) IL161587A0 (enExample)
MX (1) MXPA04003742A (enExample)
MY (1) MY127797A (enExample)
NO (2) NO331896B1 (enExample)
NZ (1) NZ532999A (enExample)
PE (1) PE20030527A1 (enExample)
PL (1) PL216535B1 (enExample)
PT (1) PT1439829E (enExample)
SI (1) SI1439829T1 (enExample)
WO (2) WO2003035054A1 (enExample)
ZA (1) ZA200403928B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE50312678D1 (de) 2002-11-22 2010-06-10 Gruenenthal Gmbh Verwendung von (1R, 2R)-3-(3-Dimenthylamino-1-ethyl-2-methyl-propyl)-phenol zur Behandlung von Entzündungsschmerz
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
ES2291780T3 (es) 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AR053304A1 (es) * 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CN101431990B (zh) * 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合
CN102675136B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX2010005680A (es) * 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
HRP20170481T1 (hr) * 2007-12-07 2017-05-19 Grünenthal GmbH Kristalne modifikacije (1r, 2r)-3-(3-dimentil amino-1-etil-2-metil-propil) fenola
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
SI2352494T1 (sl) 2008-10-30 2019-12-31 Gruenenthal Gmbh Nove in potentne dozirne oblike tapentadola
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
MX2012012509A (es) 2010-06-30 2012-12-05 Gruenenthal Gmbh Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
PT3650439T (pt) 2010-07-23 2021-03-03 Gruenenthal Gmbh Sais ou cocristais de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
PL2680833T3 (pl) 2011-03-04 2016-08-31 Gruenenthal Gmbh Pozajelitowe podawanie tapentadolu
EP3685827A1 (en) 2011-03-04 2020-07-29 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
PT2694050T (pt) 2011-04-05 2019-11-22 Gruenenthal Gmbh Tapentadol para uso no tratamento da dor associada à neuralgia trigeminal
SI2694049T1 (sl) 2011-04-05 2019-01-31 Gruenenthal Gmbh Tapentadol za preprečevanje razvoja kronične bolečine
PT2701693T (pt) 2011-04-29 2017-11-16 Gruenenthal Gmbh Tapentadol para prevenção e tratamento de depressão e ansiedade
PT3766489T (pt) 2011-05-03 2022-04-07 Gruenenthal Gmbh Composição farmacêutica aquosa semissólida contendo tapentadol
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
EP3300726A1 (en) * 2011-07-29 2018-04-04 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP6923447B2 (ja) 2015-03-27 2021-08-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与のための安定な製剤
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
EP3630074B1 (en) * 2017-05-29 2023-10-25 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
EP3875079A1 (en) * 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
ES3060121T3 (en) * 2020-03-02 2026-03-25 Gruenenthal Gmbh Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
PE20230105A1 (es) 2020-03-02 2023-01-25 Gruenenthal Chemie Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol
EP3875077B1 (en) * 2020-03-02 2023-12-13 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP4121013B1 (en) 2020-03-16 2025-01-15 Grünenthal GmbH Scored tablet comprising tapentadol
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
PE20240113A1 (es) 2020-11-10 2024-01-22 Gruenenthal Chemie Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico
RS63521B1 (sr) 2020-11-10 2022-09-30 Gruenenthal Gmbh Oblici doze sa produženim oslobađanjem soli tapentadola sa l-(+)-vinskom kiselinom

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5641631A (en) 1983-01-10 1997-06-24 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
KR100355130B1 (ko) * 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
AU694463B2 (en) 1993-11-17 1998-07-23 Lequio Pharma Co. Ltd Composition for curing lesioned tissue, process for producing the same, and use thereof
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
JP3148256B2 (ja) * 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
EP2295043A1 (en) * 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
NO20041924L (no) 2004-05-11
HUP0402104A2 (hu) 2005-03-29
PE20030527A1 (es) 2003-07-26
ECSP045102A (es) 2004-06-28
DE50204198D1 (de) 2005-10-13
ZA200403928B (en) 2005-07-27
NZ532999A (en) 2007-06-29
CY2012022I2 (el) 2015-08-05
CA2464578C (en) 2011-10-11
JP2005506367A (ja) 2005-03-03
WO2003035054A1 (de) 2003-05-01
US20050058706A1 (en) 2005-03-17
EP1439829B1 (de) 2005-09-07
BRPI0213653B1 (pt) 2018-04-03
CN1607947A (zh) 2005-04-20
US20200038344A1 (en) 2020-02-06
KR100958045B1 (ko) 2010-05-17
US20120034304A1 (en) 2012-02-09
AR036943A1 (es) 2004-10-13
EP1439829A1 (de) 2004-07-28
US20180221308A1 (en) 2018-08-09
AU2002349001B2 (en) 2003-05-06
IL161587A0 (en) 2004-09-27
IL161587A (en) 2009-12-24
WO2003035053A1 (de) 2003-05-01
PT1439829E (pt) 2005-11-30
KR20040047964A (ko) 2004-06-05
JP2010280697A (ja) 2010-12-16
NO331896B1 (no) 2012-04-30
CN100402021C (zh) 2008-07-16
JP4758064B2 (ja) 2011-08-24
HU230161B1 (en) 2015-09-28
NO2012007I1 (no) 2012-05-21
AU2002349001C1 (en) 2022-04-14
DK1439829T3 (da) 2005-10-10
MXPA04003742A (es) 2004-07-23
ES2248622T3 (es) 2006-03-16
CY2012022I1 (el) 2015-08-05
MY127797A (en) 2006-12-29
ATE303802T1 (de) 2005-09-15
NO2012007I2 (no) 2013-01-02
US20170087103A1 (en) 2017-03-30
PL216535B1 (pl) 2014-04-30
US11007156B2 (en) 2021-05-18
SI1439829T1 (sl) 2006-02-28
HK1068539A1 (en) 2005-04-29
PL369756A1 (en) 2005-05-02
US20130237608A1 (en) 2013-09-12
US20160151309A1 (en) 2016-06-02
CO5570662A2 (es) 2005-10-31
BR0213653A (pt) 2004-10-26
CA2464578A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
BR0213653A (pt) Formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo
BRPI0518266A8 (pt) Medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
AR006519A1 (es) Formula encapsulada de liberacion prolongada de clorhidrato de venlafaxina, una formula de pelicula de recubrimiento, y el uso de dicha formula encapsuladapara preparar una formulacion de liberacion prolongada
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
BR0309528A (pt) Comprimido com alta carga de droga
BR0210595A (pt) Regime de dosagem e composição farmacêutica para contracepção de emergência
MY142403A (en) Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
BRPI0508833A (pt) formulações galênicas de compostos orgánicos
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
BR0011116A (pt) Usos de uma nsaid que libera no como um sal farmaceuticamente aceitável ou um enanciÈmero do mesmo, e de uma nsaid que libera no e de um inibidor de bomba de próton suscetìvel a ácido ou um sal do mesmo ou um enanciÈmero ou de um sal do enanciÈmero, método para o tratamento de uma infecção bacteriana, e, formulação farmacêutica adequada para uso no tratamento de infecções bacterianas
CO5060477A1 (es) Forma de dosificacion de nefazodona
BR9914419A (pt) Terapia para melhoria da percepção
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
AR036312A1 (es) Composicion farmaceutica
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
BR0312921A (pt) Composição compreendendo inibidor de reductase hmg-coa
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
DE602005025339D1 (de) Flavonoide und Tocotrienole enthaltende Zusammensetzungen und deren Verwendungen
BR9917601A (pt) Composição farmacêutica para inibir a toxidade reprodutora de um macho
BR0312026A (pt) Microcápsulas para a liberação retardada e controlada do perindopril
BR0313175A (pt) Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/135, A61P 31/136, A61K 9/20, A61P 9/22, A61K 9/50, A61P 29/00

Ipc: A61K 31/135 (2011.01), A61K 9/22 (2011.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.009366/2022-39 ORIGEM: 9A VARA FEDERAL DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5051643-68.2022.4.02.5101 ACAO PELO PROCEDIMENTO ORDINARIO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: GRUENENTHAL GMBH REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI